EUVIMEDEUVIMED entdecken
BeobachtungsstudieKohortenstudieOpen Access · CC BY 4.0

Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002–17

Sarah Larney iD, Nicola R Jones iD, Matthew Hickman iD, Suzanne Nielsen iD, Robert Ali, Louisa Degenhardt iD

Addiction · 2023

DOI: 10.1111/add.16178 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Addiction, 2023. Verfasst von Sarah Larney und 5 weiteren Autor:innen. Beteiligte Einrichtung: Centre de recherche du Centre hospitalier de l'Université de Montréal, Montreal, Canada. Hauptthemen laut MEDLINE: Opiate Overdose, Opioid-Related Disorders, Buprenorphine, Drug Overdose. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDA NIH HHS, Department of Health, National Institutes of Health.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

To quantify the association between opioid agonist treatment (OAT) and overdose death by age group; test the hypothesis that across different age groups, opioid overdose mortality is lowest during OAT with buprenorphine compared with time out of treatment or OAT with methadone; and test associations between OAT and opioid overdose mortality in the presence of chronic circulatory, respiratory, liver and kidney diseases.

Design

Retrospective observational cohort study using linked administrative data.

Setting

New South Wales, Australia.

Participants

A total of 37 764 people prescribed OAT, 1 August 2002 and 31 December 2017.

Measurements

OAT exposure, opioid overdose mortality and key confounders were measured using linked population data sets on OAT entry and exit, hospitalization, mental health care, incarceration and mortality. ICD‐10 codes were used to define opioid overdose mortality and chronic disease groups of interest.

Findings

Relative to time out of treatment, time in OAT was associated with a lower risk of opioid overdose death across all age groups and chronic diseases. Among people aged 50 years and older, there was weak evidence that buprenorphine may be associated with greater protection against opioid overdose death than methadone [generalized estimating equation (GEE) adjusted incident rate ratio (aIRR) = 0.47; 95% confidence interval (CI) = 0.21, 1.02; marginal structural models (MSM) aIRR = 0.49; 95% CI = 0.17, 1.41]. Buprenorphine was associated with greater protection against overdose death than methadone for clients with circulatory (MSM aIRR = 0.27; 95% CI = 0.11, 0.67) or respiratory (MSM aIRR = 0.26; 95% CI = 0.07, 0.94) diseases, but not liver (MSM aIRR = 0.59; 95% CI = 0.14, 2.43) or kidney (MSM aIRR = 1.16; 95% CI = 0.31, 4.36) diseases.

Conclusions

Opioid agonist treatment (OAT) appears to reduce mortality risk in people with opioid use disorder who are older or who have physical comorbidities. Opioid overdose mortality during OAT with buprenorphine appears to be lower and reduced in clients with circulatory and respiratory diseases compared with OAT with methadone.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Opiate OverdoseOpioid-Related DisordersBuprenorphineDrug OverdoseHumansMiddle AgedAgedAnalgesics, OpioidCohort StudiesNew South WalesOpiate Substitution TreatmentRetrospective StudiesMethadoneAustralia

Stichwörter der Autor:innen

Buprenorphinecomorbiditymethadonemulti-morbidityolder adultsopioid agonist treatmentoverdose

Substanzen

Analgesics, OpioidMethadoneBuprenorphine

Autor:innen und Institutionen

  • Centre de recherche du Centre hospitalier de l'Université de Montréal, Montreal, Canada.
  • Department of Family Medicine and Emergency Medicine, University of Montreal, Montreal, Canada.
  • National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, Australia.
  • Bristol Medical School, Bristol University, Bristol, UK.
  • Monash Addiction Research Centre, Eastern Health Clinical School, Monash University, Clayton, Australia.
  • Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia.

ORCID-Profile: Sarah Larney, Nicola R Jones, Matthew Hickman, Suzanne Nielsen, Louisa Degenhardt

Förderung

  • NIDA NIH HHS
  • Department of Health
  • National Institutes of Health
  • NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research
  • NSW Health
  • Centre for Health Record Linkage

Zitieren

APA

Larney, S., Jones, N. R., Hickman, M., Nielsen, S., Ali, R., & Degenhardt, L. (2023). Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002–17. Addiction. https://doi.org/10.1111/add.16178

Vancouver

Larney S, Jones NR, Hickman M, Nielsen S, Ali R, Degenhardt L. Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002–17. Addiction. 2023. doi:10.1111/add.16178

BibTeX
@article{Larney2023,
  author = {Larney, Sarah and Jones, Nicola R and Hickman, Matthew and Nielsen, Suzanne and Ali, Robert and Degenhardt, Louisa},
  title = {Does opioid agonist treatment reduce overdose mortality risk in people who are older or have physical comorbidities? Cohort study using linked administrative health data in New South Wales, Australia, 2002–17},
  journal = {Addiction},
  year = {2023},
  doi = {10.1111/add.16178}
}
Kostenlos starten →